Expand NRSN Menu
NRSN MENU

NRSN Latest Press Releases

-- August 31, 2026 --

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS PRNewswire 8:45 AM

-- August 13, 2026 --

NeuroSense Issues CEO Letter to Shareholders PRNewswire 9:32 AM

-- August 6, 2026 --

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada PRNewswire 11:30 AM

-- July 22, 2026 --

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS PRNewswire 8:30 AM

-- July 6, 2026 --

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" PRNewswire 8:45 AM

-- June 29, 2026 --

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS PRNewswire 9:30 AM

-- June 25, 2026 --

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease PRNewswire 9:20 AM

-- June 22, 2026 --

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots PRNewswire 9:00 AM

-- June 11, 2026 --

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS PRNewswire 9:00 AM

-- June 9, 2026 --

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition PRNewswire 9:00 AM

-- April 28, 2026 --

NeuroSense Announces Pricing of Insider-Led PIPE Financing PRNewswire 2:30 PM

-- April 6, 2026 --

NeuroSense Granted Brazilian Patent Covering PrimeC Composition PRNewswire 9:20 AM

-- April 3, 2026 --

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements PRNewswire 10:03 AM
Market Data Delayed 15 Minutes